Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
NCT05218889 ·
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer
RecruitingThis study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable advanced or metastatic pancreatic cancer.
PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 75 Years
WhereBeijing, China
SponsorChinese PLA General Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Determining Minimal Residual Disease Using ctDNA Deep Sequencing
NCT07660627 · Esophageal Adenocarcinoma, Gastric Cancer,
Pancreatic Cancer RecruitingPreoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
PhaseNA
TypeInterventional
AgeAny
WhereBrno, Czechia
SponsorMasaryk Memorial Cancer Institute
▾Tap for detailsClick for full details — eligibility, all locations, contacts TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
NCT07284277 · Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma
RecruitingThe purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields). The main questions it aims to answer are: * Is TTFields treatment safe for the patients in combination with modFOLFIRINOX? * Are participants compliant with the treatment? * Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?
PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WherePamplona, Navarre, Spain + 4 more
SponsorClinica Universidad de Navarra, Universidad de Navarra
▾Tap for detailsClick for full details — eligibility, all locations, contacts Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
NCT06250972 · Pancreatic Adenocarcinoma
RecruitingThe purpose of this study is to evaluate the efficacy of chemotherapy plus radiotherapy to patients with CA19-9-elevated Advanced Pancreatic Cancer who are not refractory to chemotherapy.
PhasePhase 3
TypeInterventional
Age18 Years – 80 Years
WhereShanghai, Shanghai Municipality, China
SponsorFudan University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
NCT06600906 · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
RecruitingThis study evaluates an investigational scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in assessing treatment response in patients with pancreatic ductal carcinoma (PDA) that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). MRI is a standard scan that helps doctors see tumors, organs, tissue, and bone. Standard contrast agents (e.g., gadolinium) are sometimes used to help make the scan images brighter, or easier to see. Hyperpolarized carbon-13 pyruvate is an experimental contrast agent that is different from standard MRI contrast in that it provides information on how a tumor processes nutrients. Hyperpolarized carbon-13 pyruvate MRI scans may work better than MRI with standard contrast agents in predicting how PDA tumors respond to treatment.
Phase—
TypeObservational
Age18 Years
WhereSan Francisco, California, United States
SponsorUniversity of California, San Francisco
▾Tap for detailsClick for full details — eligibility, all locations, contacts This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, or cholangiocarcinoma will undergo 68Ga-SorB PET/CT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET/CT, using pathology results and/or clinical follow-up as the reference standard. The primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET/CT and 18F-FDG PET/CT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.
PhaseNA
TypeInterventional
Age18 Years
WhereBeijing, Beijing Municipality, China
SponsorPeking University Third Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts The imPAct of nutritioN on the Outcome of pancrEATic Surgery; Food for Thought.
NCT07940309 · Chronic Pancreatitis,
Pancreatic Cancer, Periampullar Disease
RecruitingPatients with cancer or chronic inflammatory disorders, such as periampullary malignancies or chronic pancreatitis (CP), often experience severe weight loss and a progressive decline in health and functional performance. These changes result from a complex interaction between the disease and the host, affecting multiple physiological factors. However, in daily clinical practice the focus is predominantly placed on treatment of the disorder itself, whereas less attention is given to the physical condition of the patient before treatment commences. Factors such as malnutrition, reduced aerobic fitness, and adverse body composition have all been associated with worse outcomes, including a higher risk of postoperative complications or inability to complete oncological treatment. The central hypothesis of the investigators is that improving the patient's overall condition before treatment, particularly before major surgery, will enhance treatment tolerance, reduce complications, and improve overall quality of life (QoL). Among the various modifiable factors in the disease-host interaction, nutritional status occupies a central role, directly influencing muscle mass and strength, immune competence, metabolic stability, and recovery capacity.
Phase—
TypeObservational
Age18 Years
WhereMaastricht, Netherlands
SponsorMaastricht University Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
NCT07481357 · Gastric (Stomach) Cancer, GastroEsophageal Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
RecruitingThe goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC. Participants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.
PhasePhase 1
TypeInterventional
Age19 Years
WhereSeongnam, Bundang, South Korea + 2 more
SponsorDong-A ST Co., Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
NCT07631871 · Neoplasms, Solid Tumors, HER2 Positive Solid Tumor
RecruitingThe goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg/kg per cycle.
PhasePhase 2
TypeInterventional
Age18 Years
WhereShanghai, Shanghai Municipality, China
SponsorHaihua Yuan
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615 · Advanced Solid Tumor
RecruitingThis is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
PhasePhase 1 / Phase 2
TypeInterventional
AgeAny
WhereHefei, Anhui, China + 31 more
SponsorJacobio Pharmaceuticals Co., Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089 · Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation
RecruitingJohns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
PhasePhase 3
TypeInterventional
Age18 Years
WhereNew Haven, Connecticut, United States + 8 more
SponsorJohns Hopkins University
▾Tap for detailsClick for full details — eligibility, all locations, contacts NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
NCT06405490 · Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin
RecruitingThis study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.
PhasePhase 2
TypeInterventional
Age18 Years
WhereBeijing, Beijing Municipality, China
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
▾Tap for detailsClick for full details — eligibility, all locations, contacts Increasing Germline Genetic Testing for Patients With Cancer
RecruitingGermline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test ordering by oncology care teams (i.e., mainstreaming) for eligible patients with breast, pancreatic or colorectal cancer. Secondarily, the study will investigate completion of testing by eligible patients, as well as impact on overall rates of germline test ordering in patients with cancer. The network will bundle and deploy different implementation strategies across the clinical sites in three 6-month phases. A maintenance phase after the implementation periods will measure genetic testing rates without any additional implementation strategies to determine persistence of effects. The implementation strategies address clinician-level factors, and thus oncologists and their team members (e.g. advanced practice providers, nurse navigators, case managers) will be the focus of evaluating the impact of implementation strategies. Strategies that will be considered include provider education, audit and feedback reports, facilitation, peer support, and electronic health record (EHR) system optimization to support germline testing. Using the RE-AIM QuEST framework, outcomes will be assessed using mixed methods separately for each eligible cancer type. Data collection from the EHR, other relevant data sources, and qualitative provider feedback will be used to assess ordering and completion of tests and the effect of the implementation strategies on germline testing rates in oncology clinics.
PhaseNA
TypeInterventional
AgeAny
WhereLos Angeles, California, United States + 9 more
SponsorJosh Peterson
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
RecruitingESSIGHT-HJG-ES502-01 is a dose-escalation study of ES502 in patients with advanced pancreatic cancer. The study will enroll patients with advanced, RAS G12V positive pancreatic cancer who have no effective treatment options available (HLA genotyping required).
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years
WhereShanghai, Shanghai Municipality, China
SponsorRuijin Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts IDOV-Immune for Advanced Solid Tumors
RecruitingThis is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
PhasePhase 1
TypeInterventional
Age18 Years
WhereSt Louis, Missouri, United States + 4 more
SponsorViroMissile, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Prognostic Factors in Periampullary Tumors and Cysts
NCT05155878 · Pancreas Cancer, Pancreas Neoplasm, Pancreas Cyst
RecruitingThe project aims at analysing prognostic and predictive factors involved in diagnostics and surgical treatment of cysts and tumors in the pancreas and periampullary region using both clinical data and blood and tissue samples for biomarker development and validation.
Phase—
TypeObservational
Age18 Years
WhereUmeå, Sweden
SponsorUmeå University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Histotripsy x Pancreatic Cancer
NCT07873606 · Pancreatic Tumours
RecruitingPancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, with 5-year survival around 12% despite advances in surgery, chemotherapy, and radiotherapy. Existing ablative therapies (RFA, microwave, irreversible electroporation) are limited by thermal injury risk, proximity to vessels/ducts. Novel local therapies that can be integrated with systemic regimens are urgently needed. Histotripsy is a non-thermal focused ultrasound modality that uses controlled cavitation to mechanically liquefy tissue without thermal coagulation or ionizing radiation, with precision under real-time ultrasound guidance. Preclinical and early translational work in pancreatic models shows that histotripsy can safely ablate pancreatic tissue while sparing major vessels and ducts in large-animal models, and can alter the tumour microenvironment (TME) with increased release of damage-associated molecular patterns (DAMPs), enhanced dendritic cell and macrophage activation, and increased CD8+ T-cell infiltration in murine pancreatic tumours. This proposal aims to evaluate the safety, local tumour control, and immunologic effects of histotripsy in pancreatic cancer especially PDAC, positioning it as a platform to enhance responsiveness to contemporary systemic therapies. The HistoSonics Histotripsy System is now registered in the Medical Device Administration Control System from Department of Health in Hong Kong (HKMD no: 252842).
PhaseNA
TypeInterventional
Age18 Years
WhereHong Kong, Hong Kong
SponsorThe University of Hong Kong
▾Tap for detailsClick for full details — eligibility, all locations, contacts PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
RecruitingThis is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.
PhasePhase 1
TypeInterventional
Age18 Years
WhereOrange, California, United States
SponsorUniversity of California, Irvine
▾Tap for detailsClick for full details — eligibility, all locations, contacts Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
RecruitingThis is a prospective, observational cohort study (MIND-PANC) to explore the associations of chronic psychological stress with disease progression, treatment outcomes, and prognosis of pancreatic cancer. Researchers will ask participants to fill out simple questionnaires about their mood, worries, and sleep at the start of the study and at regular follow-up visits. The study will also collect a small blood sample (leftover from routine care) to measure stress-related markers. Investigators hypothesize that pancreatic cancer patients who have higher levels of ongoing psychological stress (such as anxiety, depression, or poor sleep) tend to have shorter survival times, a higher chance of recurrence, and a poorer response to treatment, compared to patients with lower stress levels.
Phase—
TypeObservational
Age18 Years
WhereChangsha, Hunan, China + 2 more
SponsorShanghai Zhongshan Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
NCT07808164 · HCC - Hepatocellular Carcinoma,
CRC (Colorectal Cancer), Gastric Carcinoma
RecruitingThis Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor samples using immunohistochemistry (IHC). The study involves no investigational treatments or participant-facing procedures. Tumor samples used in this study consist exclusively of archived formalin-fixed paraffin- embedded (FFPE) tumor samples that were collected as part of routine clinical diagnosis or treatment and for which all required procedures for standard clinical care have been completed. Only archived tumor samples obtained from routine clinical care will be included in this study. No additional biopsy, surgical resection, or specimen collection will be performed for research purposes, and no sample will be diverted prior to completion of clinical requirements. All included archived tumor samples will undergo ENPP1, cGAS, and FAP IHC analysis according to the procedures specified in the Laboratory Manual.
Phase—
TypeObservational
Age18 Years
WhereHanoi, Hanoi, Vietnam + 1 more
SponsorTam Anh Research Institute
▾Tap for detailsClick for full details — eligibility, all locations, contacts